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background
 
Patients with permanent neonatal diabetes usually present within the first three months
of life and require insulin treatment. In most, the cause is unknown. Because ATP-sensi-
tive potassium (K
 
ATP
 
) channels mediate glucose-stimulated insulin secretion from the
pancreatic beta cells, we hypothesized that activating mutations in the gene encoding
the Kir6.2 subunit of this channel (
 
KCNJ11
 
) cause neonatal diabetes.
 
methods
 
We sequenced the 
 
KCNJ11
 
 gene in 29 patients with permanent neonatal diabetes. The in-
sulin secretory response to intravenous glucagon, glucose, and the sulfonylurea tolbu-
tamide was assessed in patients who had mutations in the gene.
 
results
 
Six novel, heterozygous missense mutations were identified in 10 of the 29 patients. In
two patients the diabetes was familial, and in eight it arose from a spontaneous muta-
tion. Their neonatal diabetes was characterized by ketoacidosis or marked hyperglyce-
mia and was treated with insulin. Patients did not secrete insulin in response to glucose
or glucagon but did secrete insulin in response to tolbutamide. Four of the patients also
had severe developmental delay and muscle weakness; three of them also had epilepsy
and mild dysmorphic features. When the most common mutation in Kir6.2 was coex-
pressed with sulfonylurea receptor 1 in 
 
Xenopus laevis
 
 oocytes, the ability of ATP to block
mutant K
 
ATP
 
 channels was greatly reduced.
 
conclusions
 
Heterozygous activating mutations in the gene encoding Kir6.2 cause permanent neo-
natal diabetes and may also be associated with developmental delay, muscle weakness,
and epilepsy. Identification of the genetic cause of permanent neonatal diabetes may
facilitate the treatment of this disease with sulfonylureas.
abstract
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eonatal diabetes may be defined
 
as insulin-requiring hyperglycemia that is
diagnosed within the first three months
of life. It may be either transient, resolving within
a median of three months, or permanent, in which
case insulin treatment is required for life.
 
1
 
 Substan-
tial progress has been made in our understanding
of transient neonatal diabetes, with the majority of
cases being attributable to an abnormality in an
imprinted region of chromosome 6.
 
2
 
 In most pa-
tients, the cause of permanent neonatal diabetes is
unknown; homozygous and compound heterozy-
gous mutations in the gene encoding glucokinase
account for a minority of cases,
 
3-6
 
 and the genes
for some very rare, multisystem conditions that in-
clude neonatal diabetes have been identified.
 
7-9
 
ATP-sensitive potassium (K
 
ATP
 
) channels play a
central role in glucose-stimulated insulin secretion
from pancreatic beta cells: insulin secretion is initi-
ated by closure of the channels and inhibited by their
opening (Fig. 1).
 
10
 
 The beta-cell K
 
ATP
 
 channel is an
octameric complex of four pore-forming, inward-
ly rectifying potassium-channel subunits (Kir6.2)
and four regulatory sulfonylurea-receptor subunits
(SUR1).
 
11
 
 Both Kir6.2 and SUR1 are required for
correct metabolic regulation of the channel: ATP
closes the channel by binding to Kir6.2, and magne-
sium nucleotides (Mg-ADP and Mg-ATP) stimulate
channel activity by interacting with SUR1. Sulfonyl-
ureas stimulate insulin secretion in type 2 diabetes
by binding to SUR1 and closing K
 
ATP
 
 channels by an
ATP-independent mechanism.
 
10
 
We hypothesized that activating mutations in the
gene encoding the Kir6.2 subunit of the beta-cell
K
 
ATP
 
 channel (
 
KCNJ11
 
) cause monogenic diabetes,
because inactivating mutations in this gene lead to
uncontrolled insulin secretion and congenital hy-
perinsulinism.
 
12
 
 The contrasting phenotypes of per-
manent neonatal diabetes and hyperinsulinism are
seen with inactivating and activating mutations, re-
n
 
Figure 1. Schematic Representation of the Pancreatic Beta Cell, Illustrating the Role of the ATP-Sensitive Potassium 
(K
 
ATP
 
) Channel in Insulin Secretion.
 
Glucose enters the beta cell by way of the GLUT2 glucose transporter. Once inside the cell, glucose is metabolized, lead-
ing to changes in the intracellular concentration of adenine nucleotides that inhibit the K
 
ATP
 
 channel and thus cause 
channel closure. The K
 
ATP
 
 channel consists of four sulfonylurea-receptor (SUR1) subunits and four Kir6.2 subunits in 
an octomeric structure. Channel closure leads to membrane depolarization, which subsequently activates voltage-
dependent calcium (Ca
 
2+
 
) channels, leading in turn to an increase in intracellular Ca
 
2+
 
, which triggers insulin exocytosis. 
Sulfonylureas initiate secretion by directly binding to the SUR1 subunits of K
 
ATP
 
 channels and causing channel closure. 
Mg-ADP denotes magnesium ADP.
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spectively, of the gene encoding glucokinase.
 
3,13,14
 
Strong support for our hypothesis comes from the
observation that transgenic mice with overactive
beta-cell K
 
ATP
 
 channels have profound neonatal dia-
betes.
 
15
 
 We therefore sequenced the gene encoding
Kir6.2 in patients who had permanent neonatal di-
abetes or dominantly inherited maturity-onset dia-
betes of the young (MODY).
 
patients
 
We sequenced the DNA of 29 probands with perma-
nent neonatal diabetes, mainly from the Interna-
tional Society for Pediatric and Adolescent Diabe-
tes (ISPAD) Rare Diabetes Collection. Patients were
registered in the collection or were recruited for the
methods
 
Figure 2. Diabetes Status and Mutations in the Gene Encoding Kir6.2 in 10 Families.
 
These partial pedigrees show families with the Q52R, V59G, V59M, R201C, R201H, and I296L mutations. In all the pedigrees for which paren-
tal DNA was available, family relationships were confirmed by a panel of 10 microsatellites. In ISPAD pedigrees 19, 22, 27, 41, 43, 44, 54, and 
55, spontaneous mutations explain the absence of permanent neonatal diabetes in the parents and its presence in a child. Squares represent 
male family members, circles female family members, and diamonds sex not defined; blue circles and squares represent persons with neo-
natal diabetes; a slash mark indicates deceased. The numbers inside diamonds indicate the number of unaffected siblings. A two-letter code 
for allele status is shown underneath each symbol: N denotes no mutation, M mutation, and NA not available for testing. P and an arrow 
denote the proband in each family (the first affected member recruited for this study). Amino acids are denoted by their single-letter codes.
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study between September 2001 and October 2003.
Patients with abnormalities in chromosome 6q24,
mutations in the gene encoding glucokinase, exo-
crine pancreatic insufficiency, and pancreatic agen-
esis were excluded. We also sequenced the DNA of
15 probands with MODY from families in the Unit-
ed Kingdom in whom mutations in the six known
MODY-associated genes had been ruled out.
 
16
 
 Writ-
ten informed consent was obtained from all the pa-
tients or their parents.
 
mutational analyses
 
The coding region and the intron–exon boundaries
of 
 
KCNJ11
 
 were amplified from genomic DNA by
the polymerase chain reaction with the use of pre-
viously described primers
 
17
 
 in addition to fragment
5R 5'CTGTGGTCCTCATCAAGCTG3', fragment
6F 5'GCTGAGGAGGACGGACGTTAC3', and frag-
ment 6R 5'CCACATGGTCCGTGTGTACACACG3'.
The products were sequenced by standard methods.
Family relationships were confirmed with the use
of a panel of 10 microsatellite markers.
 
clinical studies
 
All patients with mutations in the gene encoding
Kir6.2 underwent clinical examinations, including
detailed developmental and neurologic assess-
ments by a consultant pediatrician or physician, and
their medical records were reviewed. Electrocardio-
grams were examined for evidence of arrhythmias
and for measurement of the QT interval. All physio-
logical tests were performed after the patients had
fasted overnight. A glucagon stimulation test was
performed as follows: 15 µg of glucagon per kilo-
gram of body weight (maximal dose, 1 mg) was giv-
en intravenously at time 0, and blood samples for
measurement of C-peptide were obtained at ¡10,
¡5, 0, 2, 4, 6, 8, 10, 15, and 20 minutes. The high-
est C-peptide value was then recorded. A tolbuta-
mide-modified, frequently sampled intravenous
glucose-tolerance test was performed as previously
described.
 
18
 
 After base-line sampling, a bolus of
0.3 g of glucose per kilogram was given intravenous-
ly, followed by a bolus of 3 mg of tolbutamide per
kilogram 20 minutes later. We calculated the peak
incremental insulin response after the glucose bo-
lus and after the tolbutamide bolus.
 
functional studies
 
Wild-type mouse Kir6.2 or Kir6.2 in which histi-
dine replaced arginine at position 201 (R201H) was
coexpressed with rat SUR1 (containing exon 17) in
 
Xenopus laevis
 
 oocytes, and K
 
ATP
 
 currents were re-
corded as previously described.
 
19,20
 
 To simulate
the effect of heterozygosity, we injected oocytes
with SUR1 and a 1:1 mixture of Kir6.2 and Kir6.2-
R201H messenger RNA (mRNA). ATP concentra-
tion–response curves were fitted according to the
Hill equation: I÷I
 
C
 
=1÷[1+([ATP]÷IC
 
50
 
)
 
h
 
], where
I is the K
 
ATP
 
 current, I
 
C
 
 is the current in the absence
of nucleotide, [ATP] is the ATP concentration, IC
 
50
 
is the ATP concentration at which inhibition is half
maximal, and h is the Hill coefficient. Data are giv-
en as means ±SE.
 
mutational analyses
 
We identified six novel, heterozygous mutations in
the gene encoding Kir6.2 in 10 of the 29 probands
results
 
Figure 3. Illustration of Two Kir6.2 Subunits, Showing the Mutations Identified 
in Patients with Permanent Neonatal Diabetes.
 
The illustration is based on the crystal structure of the potassium channel 
KirBac1.1.
 
21
 
 The alpha-helical slide helix is shown in green, the selectivity filter 
in orange, and the C-terminal beta sheets in blue. The residues affected by 
mutations in patients with neonatal diabetes (Q52, V59, R201, and I296) are 
shown in yellow. Amino acids are denoted by their single-letter codes. The shad-
ed band represents the cell membrane, and the blue circles the potassium ion. 
The labels “External” and “Internal” refer to areas outside and inside the cell.
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who had permanent neonatal diabetes. The muta-
tions were a glutamine-to-arginine substitution at
position 52 (Q52R), a valine-to-glycine substitution
at position 59 (V59G), a valine-to-methionine sub-
stitution at position 59 (V59M), an arginine-to-
histidine substitution at position 201 (R201H), an
arginine-to-cysteine substitution at position 201
(R201C), and an isoleucine-to-leucine substitution
at position 296 (I296L). No mutations were found
in any of the probands who had MODY. The R201H
missense mutation was identified in 4 of these 10
probands, and the V59M missense mutation was
detected in 2. In all the families, neonatal diabetes
was seen only in persons who had Kir6.2 mutations,
and all family members who did not have these
mutations were not diabetic (Fig. 2).
In two families (ISPAD 19 and BR 1), neonatal di-
abetes had been transmitted from an affected par-
ent to his or her offspring. Because both maternal
and paternal transmission can occur, imprinting of
this locus is unlikely. In nine cases, DNA was avail-
able from both unaffected parents, and paternity
was established; the mutations were shown to have
arisen spontaneously. None of the mutations were
present in 100 nondiabetic subjects from the United
Kingdom.
Figure 3 shows the location of mutated residues
in Kir6.2. All the mutated residues are conserved
among humans, rats, mice, and bullfrogs. The ar-
ginine residue at position 201 is conserved among
10 members of the family of Kir channels, a find-
ing that supports the possibility that this residue has
a critical role in channel function. In addition, we
identified several previously recognized polymor-
phisms (a glutamic acid–to–lysine substitution at
position 23 [E23K], a silent alanine-to-alanine sub-
stitution at position 190 [A190A], a silent leucine-
to-leucine substitution at position 267 [L267L],
a leucine-to-valine substitution at position 270
[L270V], an isoleucine-to-valine substitution at
position 337 (I337V], a silent lysine-to-lysine sub-
stitution at position 381 [K381K], and a serine-to-
cysteine substitution at position 385 [S385C]).
 
clinical characteristics
 
The clinical characteristics of patients with muta-
tions are shown in Table 1. There were two sub-
groups of patients: those who had only diabetes and
those who had diabetes and shared neurologic ab-
normalities. Diabetes and low birth weight reflect
impaired intrauterine and postnatal insulin secre-
tion and were similar in the two subgroups of pa-
tients.
 
Diabetes
 
Diabetes was diagnosed at a mean age of 7 weeks
(range, birth to 26 weeks). At diagnosis, all the pa-
tients had marked hyperglycemia (glucose concen-
tration, 270 to 972 mg per deciliter [15 to 54 mmol
per liter]), and three had ketoacidosis. None of the
patients had elevated concentrations of autoanti-
bodies associated with type 1 diabetes, and the
C-peptide concentration was usually less than
200 pmol per liter. The median dose of insulin was
0.8 U per kilogram (range, 0.3 to 1.3). Only one pa-
tient (the proband’s father in family BR 1) was not
treated with insulin. He had received tolbutamide
since childhood, and at 46 years of age, he had good
control of the disease with this medication (fasting
glucose concentration, 110 mg per deciliter [6.1
mmol per liter]; C-peptide concentration, 400 pmol
per liter).
 
Low Birth Weight
 
Low birth weight was a feature of all the patients; in
7 of 12 (58 percent) the birth weight was at or be-
low the 3rd percentile. Patients who did not have
neurologic symptoms (Table 1) showed marked
catch-up growth after birth, and their weights and
heights were normally distributed on follow-up
after a mean of 9.3 years.
 
Neurologic Features
 
Three of the patients (the probands in families
ISPAD 25, ISPAD 27, and ISPAD 43) had very sim-
ilar neurologic abnormalities, which suggested
extrapancreatic phenotypes associated with their
Kir6.2 mutation (Table 1). All three had marked de-
velopmental delay, muscle weakness, epilepsy, and
dysmorphic features as well as neonatal diabetes.
Another patient (the proband in family ISPAD 55)
had an intermediate phenotype involving severe de-
velopmental delay and muscle weakness in addi-
tion to neonatal diabetes, but no other neurologic
features. No cause other than their Kir6.2 mutation
was found for their neurologic problems. All chil-
dren had normal karyotypes. The other patients had
normal development, indicating that not all muta-
tions in Kir6.2 are associated with neurologic ab-
normalities.
 
Developmental Delay
 
All four patients with common neurologic features
had marked developmental delay involving failure
to achieve motor, intellectual, and social milestones
appropriate for their age. The motor delay was the
most marked of these features; the oldest child was
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unable to walk unaided at the age of 17 years, and
all four children showed motor development that
was consistent with that of children half their chron-
ologic age or younger. There was muscular weak-
ness on neurologic examination in all four cases.
The creatine kinase concentration was normal in all
of them. Muscle-biopsy specimens obtained from
two of the patients were normal, and electromyog-
raphy performed in two confirmed that nerve con-
duction was normal. In one patient action potentials
of decreased duration and amplitude suggested a
myopathy.
Social and language development was also mark-
edly delayed in these four patients. None of them
had microcephaly, and magnetic resonance imaging
(MRI) and computed tomographic studies showed
no reduction in the size of the cortex or cerebellum.
No structural abnormalities were seen, apart from
small, nonspecific, generalized patches throughout
the white matter in one patient (the proband in
family ISPAD 43) on an MRI scan obtained when she
was 14 years of age.
 
Epilepsy
 
Generalized seizures, either complex or myoclonic,
were observed in three patients (the probands in
families ISPAD 25, ISPAD 27, and ISPAD 43) begin-
ning in the first year of life. The seizures responded
to antiepileptic medication (vigabatrin in two pa-
tients and sodium valproate in one). The seizures
preceded clinically recognized episodes of hypogly-
cemia. All electroencephalograms showed general-
ized abnormal activity with bilateral sharp waves.
One patient had marked hypsarrhythmia, which re-
sponded to vigabatrin.
 
Dysmorphic Features
 
All three patients with epilepsy had mild dysmor-
phic features (see Supplementary Appendix 1, avail-
able with the full text of this article at www.nejm.
org). Their appearance was characterized by a prom-
inent metopic suture, a downturned mouth, and bi-
lateral ptosis. All three patients had limb contrac-
tures, which were diagnosed at birth in two and at
four years of age in one.
 
physiological studies
 
Both during fasting and after glucagon stimulation,
the serum C-peptide concentration was generally
less than 200 pmol per liter, despite marked hyper-
glycemia — a finding consistent with profound
beta-cell dysfunction (Table 1). Serum C-peptide ex-
ceeded the lower limit of the normal range in only
three patients (two insulin-treated children and the
adult whose diabetes was well controlled with tol-
butamide) (Table 1). Three patients, who had mu-
tations affecting residue 201, had only minimal in-
sulin secretion in response to intravenous glucose
but did secrete insulin in response to tolbutamide
(Fig. 4).
 
functional analysis of the r201h mutation
 
When wild-type Kir6.2 was coexpressed with SUR1
in 
 
X. laevis
 
 oocytes, K
 
ATP
 
 currents were almost un-
detectable because of inhibition by high intracellu-
lar ATP concentrations, but they could be activated
by azide, which lowers cytosolic ATP concentrations
(Fig. 5A). In contrast, significant resting currents
were recorded from oocytes expressing Kir6.2-
R201H–SUR1 (P<0.01 for the comparison with
wild-type Kir6.2). These currents were further ac-
tivated by azide (P<0.05 for the comparison with
wild-type Kir6.2) and were blocked by tolbutamide,
indicating that they flow through K
 
ATP
 
 channels
(Fig. 5B and 5C). These data suggest that metabo-
lism causes less blockade of Kir6.2-R201H–SUR1
channels than it does of wild-type K
 
ATP
 
 channels.
To explore the mechanisms underlying these
findings, we examined the nucleotide sensitivity of
wild-type and mutant channels in inside-out patch-
es (Fig. 5D). Kir6.2-R201H–SUR1 channels were
considerably less sensitive than wild-type channels
to intracellular ATP; mutant channels were half
maximally blocked at an ATP concentration of
 
Figure 4. Insulin Secretory Responses to Intravenous Glucose and to Tolbu-
tamide.
 
The results are presented as the peak increase in the insulin level from base 
line in response to 0.3 g of intravenous glucose per kilogram and 3 mg of in-
travenous tolbutamide per kilogram for three members of ISPAD families 19 
and 41.
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262±33 µM, as compared with an ATP concentration
of 7±1 µM for Kir6.2–SUR1 channels (P<0.001)
(Fig. 5E). However, mutant channels were activated
by Mg-ADP to a similar extent. The single-channel
conductance and the fraction of time the channel
spends in the open state (the “open probability”)
were normal.
To simulate the effect of heterozygosity, we in-
jected oocytes with SUR1 and a 1:1 mixture of
Kir6.2 and Kir6.2-R201H mRNA. The resting cur-
rent of oocytes injected with the 1:1 mixture was
slightly, but not significantly, greater (0.27±0.07 nA)
than that of oocytes with the wild-type channel
(0.13±0.05 nA) (P=0.12) (Fig. 5C). The K
 
ATP
 
 cur-
rents of mutant channels were further activated
by azide and blocked by tolbutamide, to an extent
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Figure 5. The Effects of Metabolic Inhibition, a Sulfonyl-
urea, and Intracellular ATP on Currents in Wild-Type 
and Mutant ATP-Sensitive Potassium (K
 
ATP
 
) Channels.
 
Whole-cell currents were recorded in a two-electrode volt-
age clamp from intact oocytes expressing Kir6.2–SUR1 
(Panel A) or Kir6.2-R201H–SUR1 (Panel B) in response 
to voltage steps of ±20 mV from a holding potential of 
¡10 mV. The external solution consisted of 90 mM potas-
sium chloride, 1 mM magnesium chloride, 1.8 mM calci-
um chloride, and 5 mM HEPES (pH 7.4 with potassium 
hydroxide), plus 3 mM azide and 500 µM tolbutamide as 
indicated. Panel C shows the mean whole-cell current 
evoked by a voltage step from ¡10 to ¡30 mV in control 
solution, then after steady state was reached with 3 mM 
azide, then in the continued presence of azide plus 500 
µM tolbutamide. Oocytes were injected with messenger 
RNA encoding SUR1 plus either Kir6.2 (six oocytes), 
Kir6.2-R201H (seven), or a 1:1 mixture of Kir6.2 and 
Kir6.2-R201H (seven). The T bars represent standard 
errors. Panel D shows the K
 
ATP
 
 current recorded in re-
sponse to voltage ramps from ¡110 to +100 mV from 
an inside-out patch excised from an 
 
X. laevis
 
 oocyte co-
expressing SUR1 and either wild-type or mutant Kir6.2, 
as indicated. The dashed line indicates the zero current 
level. The pipette solution consisted of 140 mM potas-
sium chloride, 1.2 mM magnesium chloride, 2.6 mM 
calcium chloride, and 10 mM HEPES (pH 7.4 with potas-
sium hydroxide). The internal solution consisted of 107 
mM potassium chloride, 1 mM potassium sulfate, 1 mM 
calcium chloride, 10 mM EGTA (egtazic acid), 10 mM 
HEPES (pH 7.2 with potassium hydroxide), and 100 µM 
ATP, as indicated. Panel E shows the relation between 
the ATP concentration and the K
 
ATP
 
 current, expressed 
relative to the current in the absence of nucleotide, for 
Kir6.2–SUR1 in six oocytes (open circles), Kir6.2-R201H–
SUR1 in six oocytes (solid circles), and a 1:1 mixture of 
Kir6.2-R201H and Kir6.2 coexpressed with SUR1 in six 
oocytes (diamonds). The lines are the best fit of the Hill 
equation to the mean data: for Kir6.2–SUR1, the concen-
tration at which inhibition is half maximal (IC
 
50
 
) is 6.6 
µM, and the Hill coefficient (h) is 1.1; for Kir6.2-R201H–
SUR1, IC
 
50
 
 is 245 µM and h is 2. For the 1:1 mixture, the 
line is the best fit to the following equation: a(1÷[1+ 
([ATP]÷245 µM)
 
2
 
]) +(1¡a)(1÷[1+([ATP]÷IC
 
50
 
)
 
h
 
]), where 
[ATP] is the ATP concentration, IC
 
50
 
 is 7.6 µM, h is 1.6, and 
a (the fraction of the homomeric R201H channels) is 0.04.
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similar to that in the wild-type channel. The ATP
sensitivity was also close to that of the wild-type
channel, with an IC
 
50
 
 value of 7.6±0.4 µM (Fig. 5E).
However, the K
 
ATP
 
 currents of mutant channels
were significantly larger than those of wild-type
channels at ATP concentrations of 1 µM (P=0.002)
and 3 µM (P=0.008), due to the difference in the
Hill coefficient.
Our findings show that heterozygous activating
mutations in the gene encoding the Kir6.2 subunit
of the K
 
ATP
 
 channel can cause both familial and
sporadic neonatal diabetes. This genetic subtype
may be a relatively common cause of permanent
neonatal diabetes, since we found it in 34 percent
of probands. Some patients with mutations in the
gene encoding Kir6.2 have marked developmental
delay, muscle weakness, and epilepsy, in addition to
neonatal diabetes. These observations point to the
critical role of K
 
ATP
 
 channels in pancreatic beta cells
and suggest a role in human muscle and brain.
The evidence that these mutations are causal is
very strong. They cosegregated with diabetes in the
two families with vertical transmission, and the
nonfamilial cases of diabetes were associated with
spontaneous mutations (since the mutation was not
present in the normoglycemic parents). Approxi-
mately 1 in 10
 
6
 
 people is likely to have a spontane-
ous mutation in a gene of this size, so nine such
mutations is highly unlikely to be a chance obser-
vation. The most common mutation (resulting in
the R201H substitution) occurs within a CpG dinu-
cleotide, a “hot spot” for mutations in mammalian
genes. This probably explains the recurrent finding
of the R201H mutation in unrelated families from
different countries. Since the majority of the muta-
tions are spontaneous, a family history of diabetes is
frequently not present.
Diabetes was diagnosed at a mean age of seven
weeks and within the first three months of life in 10
of the 13 patients. Although three patients present-
ed with ketoacidosis, it is likely that at least some
patients had minimal secretion of endogenous in-
sulin, since in most patients the disease was not di-
agnosed immediately after birth, and some had de-
tectable C-peptide concentrations. Patients with
Kir6.2 mutations may show some overlap with
type 1 diabetes in terms of clinical features, but none
of our patients had beta-cell autoantibodies. The ex-
tent to which mutations in the gene encoding Kir6.2
account for antibody-negative type 1 diabetes re-
quires investigation.
The severe intrauterine growth retardation found
in the patients with Kir6.2 mutations is consistent
with greatly reduced or absent insulin secretion in
utero and is also seen in patients with glucokinase
deficiency, loss of an imprinted region of chromo-
some 6q24 (which results in transient neonatal
diabetes), and pancreatic agenesis.
 
2,3,7,23 Marked
postnatal catch-up growth is a feature of these
conditions and was also observed in the patients
with Kir6.2 mutations who did not have neurologic
abnormalities.
Mutations in the gene encoding Kir6.2 probably
cause decreased secretion of insulin from beta cells
by conferring reduced sensitivity to ATP, which is
predicted to result in gain of channel function.
Functional analysis of the most common mutation,
R201H, showed that the homozygous mutation led
to markedly reduced sensitivity to ATP. When wild-
type and mutant subunits were coexpressed to sim-
ulate the heterozygous state, the ATP sensitivity of
the resulting mixed population of heteromeric chan-
nels was similar to that of the wild type, except at
low ATP concentrations. However, we expect that
there will be a small population of homomeric
R210H channels with lower ATP sensitivity (about
6 percent of the channels if the number of mutant
subunits in the tetrameric channel is binomially dis-
tributed). Indeed, such ATP-insensitive channels
were observed at the single-channel level (data not
shown). Although this current is difficult to mea-
sure at high ATP concentrations, it may be sufficient
to keep the beta cell hyperpolarized even in the pres-
ence of glucose, thereby reducing electrical activity
and insulin release. Our results indicate that very
small changes in the resting KATP current, due to
small changes in ATP sensitivity, can impair insulin
secretion sufficiently to cause diabetes in humans.
This finding is consistent with some24 but not all25
in vitro studies that suggest that a Kir6.2 polymor-
phism in which lysine replaces glutamic acid at po-
sition 23 (E23K) shows small changes in ATP sensi-
tivity.
A molecular model of the C terminal of Kir6.226
predicts that R201 lies close to the phosphate tail of
ATP and that it interacts with the alpha phosphate
of ATP. The concept of a critical role for residue 201
in ATP binding is supported by the finding that the
ATP sensitivity of KATP channels is reduced when
the arginine at position 201 is mutated to histidine
and other residues.27,28 Three mutations (Q52R,
discussion
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V59M, and V59G) are found in the slide helix; resi-
due 52 lies at one end of the helix, and residue 59 lies
midway along its length (Fig. 3). The position of the
slide helix implies a role in the regulation of chan-
nel gating,21 but it lies distant from the predicted
ATP-binding site. Additional work is required to elu-
cidate the mechanism by which the mutations that
lie in the slide-helix domain effect disease.
Identification of mutations in the gene encoding
the KATP-channel subunit Kir6.2 may have impor-
tant implications for the treatment of affected pa-
tients. Our functional studies in vitro suggest that if
the KATP channel could be closed by an ATP-inde-
pendent mechanism (e.g., by sulfonylureas), insulin
secretion might be restored. Patients with mutations
affecting position 201 did have clear, but subnor-
mal, insulin responses to intravenous tolbutamide.
This observation suggests that the pathophysiolog-
ical condition in humans mirrors the findings in
vitro, raising the possibility of novel treatment strat-
egies based on sulfonylureas (or other specific KATP-
channel inhibitors) in these apparently insulin-
dependent patients. Of note, one patient with an
R201H mutation (the proband’s father in family
BR 1), who had always been treated with tolbuta-
mide, had C-peptide levels in the normal range and
good glycemic control. Further investigation is
needed to determine whether the identification of
a mutation in the gene encoding Kir6.2 will permit
treatment to be given in the form of oral agents rath-
er than subcutaneously injected insulin.
It is unlikely that the severe developmental delay,
muscle weakness, and epilepsy seen in a subgroup
of the patients with Kir6.2 mutations result from
diabetes or its treatment. Severe developmental de-
lay and persistent epilepsy are rare in children with
neonatal diabetes2,3,6,7; moreover, in our study, neu-
rologic diagnosis preceded clinically recognized ep-
isodes of hypoglycemia, and the contractures seen
at birth in two of the patients suggest that neuro-
logic dysfunction was present in utero. Kir6.2 is
the pore-forming subunit of KATP channels in skel-
etal muscle and neurons throughout the brain29,30;
hence, altered activity of these channels could cause
developmental delay, muscle weakness, and epi-
lepsy. Studies in animal models to assess skeletal
muscle and the neurologic effects of gain-of-func-
tion mutations have not been performed; however,
loss of function of the KATP channel can result in
hypoxia-induced seizures,31 and overexpression of
SUR1 in forebrain reduces the susceptibility to sei-
zures.32 Analysis of additional patients will be nec-
essary to determine whether Kir6.2 mutations give
rise to a discrete syndrome characterized by devel-
opmental delay, epilepsy, and neonatal diabetes.
The position and type of the mutation may influ-
ence the phenotype. All eight patients with muta-
tions at residue 201 had diabetes but no neurologic
abnormalities. The V59M variant is associated both
with isolated diabetes and with marked develop-
mental delay in addition to diabetes. This kind of
genetic behavior — one in which the same muta-
tion is associated with different phenotypes in dif-
ferent families — has been observed with other
genes, such as LMNA.33
That heterozygous mutations of Kir6.2 cause di-
abetes confirms that the KATP-channel–dependent
pathway is critical for insulin secretion and that
other, KATP-channel–independent pathways are un-
able to compensate for its loss. Mutations with a
less severe functional effect or modification by the
genetic background might lead to transient neo-
natal diabetes or to diabetes that becomes manifest
after the neonatal period. Indeed, we and others
have shown that the common Kir6.2 polymorphism
E23K is associated with a slightly increased suscep-
tibility to type 2 diabetes.24,34,35
In conclusion, activating mutations in the gene
encoding the ATP-sensitive potassium-channel sub-
unit Kir6.2 cause neonatal diabetes, and in some
patients, neurologic abnormalities. The prelimi-
nary finding that tolbutamide partly compensates
for the effect of the most common mutation on in-
sulin secretion offers hope that in at least some
cases the diabetes may be effectively treated with
sulfonylurea tablets.
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